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Abstract 
A 20-year-old female was diagnosed with ulcerative colitis (UC) at age 14 and primary 
sclerosing cholangitis (PSC) at age 16. The PSC was successfully treated with high doses of oral 
vancomycin; however, the UC was more difficult to manage. After many drug treatments failed 
to treat the UC, the patient began following the specific carbohydrate diet (SCD). This report 
documents fecal microbiome changes resulting from following the SCD for two weeks. The DNA 
extracted from fecal samples was subjected to 16S rRNA gene sequencing to quantify bacterial 
species abundance. Not only were substantial changes in the fecal bacterial composition 
detectable within two weeks, but all UC symptoms were also controlled as early as one week 
following the start of the diet. The patient's fecal microbiota was dramatically different from 
those of three healthy control subjects and showed remarkable loss of bacterial diversity in 
terms of species richness, evenness, and overall diversity measures. Other specific changes in 
bacterial composition included an increase in Enterobacteriaceae, including Escherichia and 
Enterobacter species. A two- to three-fold decrease was observed in the prevalence of the most 
dominant fecal bacterial species, Fusobacterium ulcerans, after two weeks on the SCD. Overall 
species diversity and evenness increased to levels near the controls, although species richness 
remained low. These findings provide information on the fecal bacteria from a patient with PSC 
and UC, following prolonged oral vancomycin treatment, and identifies a potentially specific 
microbial effect for the SCD. 
Categories: Miscellaneous, Gastroenterology, Other 
Keywords: fecal bacteria, ulcerative colitis, primary sclerosing cholangitis, specific carbohydrate diet, 
microbiome, 16s rrna gene sequencing 
Introduction 
Ulcerative colitis (UC) is a subtype of inflammatory bowel disease (IBD), characterized by 
immune dysregulation leading to chronic colonic inflammation. A combination of genetic 
factors and environmental triggers could result in the UC disease phenotype; however, both 
have proven difficult to identify. One of the environmental triggers could involve the intestinal 
microbiome composition [1]. 
Approximately 80-90% of primary sclerosing cholangitis (PSC) patients also suffer from UC [2]. 
The link between the two illnesses is largely unknown; however, a recent publication reveals it 
may involve T-cells of common clonal origin infiltrating the intestines and liver [3]. 
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Over the past decade, the intestinal microbiome has become a subject of intense study. 
Naturally, IBD is one of the main diseases being analyzed for pathogenic intestinal microbiome 
involvement. Dietary supplements, probiotics, and various diets have all been investigated as 
possible therapies. The specific carbohydrate diet (SCD), originally described as a treatment for 
Celiac disease in the 1920s and applied to IBD in 1987, has recently made headlines with its 
potential ability to treat IBD [4]. The SCD is a very restrictive diet, limiting most disaccharides 
and starches, with the goal of decreasing bacterial species that both feed on malabsorbed 
carbohydrates and create acids and inflammatory byproducts. Most unprocessed fruits, 
vegetables, and meat products are acceptable, while all grains, starch-heavy foods such as 
potatoes, and soft dairy products such as store-bought yogurt and milk are eliminated. 
A recent study (available as "Published Ahead-of-Print") by Suskind et al. [4] investigated the 
effects of the SCD on the microbiome of pediatric Crohn’s and UC patients. The study identified 
intestinal microbial changes in response to the SCD. The case presented here identifies 
additional potential microbial effects of the SCD in an adult UC and PSC patient. 
Case Presentation 
The patient discussed in this case report presented with symptoms of bloody diarrhea, frequent 
bowel movements, lower left quadrant abdominal pain, and fatigue in October 2009 at age 14. 
She received the diagnosis of ulcerative colitis (UC) one week following onset of symptoms 
subsequent to a colonoscopy and gastrointestinal mucosal biopsies. Numerous medications 
were prescribed in attempts to control symptoms, including mesalamine, VSL#3, Apriso, and 
hydrocortisone steroid enemas. Although each medication temporarily relieved symptoms, 
none maintained long-lasting effects. Treatment with Remicade was effective; however, 
injection reactions led the physician and patient to seek other treatment options. Subsequent 
treatment with Humira was ineffective. 
Routine blood tests over a four-month time period, when the patient was 16, detected 
increasingly elevated gamma-glutamyl transpeptidase, alanine transaminase, and aspartate 
transaminase activity. primary sclerosing cholangitis (PSC) was suspected and confirmed via 
liver biopsy in March 2011. Vancomycin (500 mg, three times daily) was prescribed, and liver 
enzymes normalized. UC symptoms remained, however, leading to increased vancomycin 
dosages to 750 mg three times daily and finally 1000 mg vancomycin three times daily. It was 
concluded that while vancomycin treated PSC in this patient, it had no beneficial effect on 
UC, and Remicade was once again administered. The patient developed an allergic reaction to 
Remicade in 2012 and discontinued treatment, instead opting to treat UC using the 
specific carbohydrate diet (SCD). For one year the patient was treated using SCD, after which 
Remicade was once again prescribed at five mg/kg every eight weeks, with no allergic reaction. 
To investigate the mode of action of the SCD, Remicade was stopped for a two-week period in 
March 2015, during which the patient, now age 20, was once again treated with the SCD.
Baseline stool samples (pre-diet 1, pre-diet 2) were collected two weeks prior to the initiation 
of the SCD, while the patient was still being treated with Remicaid, to serve as confirmation of 
microbiome composition before the SCD. A prescheduled Remicade treatment was delayed 
and the SCD was followed for two weeks, after which another stool sample was collected (post-
diet). The two-week time period was sufficient for detectable microbiome changes in previous 
literature studies [4]. Samples from three healthy subjects (volunteer college-age students; one 
male, two female) were included as controls for comparison. Control subjects' antibiotic use 
history was not collected and no dietary data were collected. All samples were analyzed by 
high-throughput sequencing of the V4 region of the 16S rRNA gene, using an Ion Torrent 
Personal Genome Machine™ sequencer (MR-DNA labs, Shallowater, TX). Between 48,000 and 
129,000 16S rRNA gene sequences passing quality control (QC) parameters were returned from 
the samples (Table 1) and assigned a taxonomic origin using the MR-DNA Lab’s 16S sequence 
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analysis protocol. 
The patient’s fecal microbiome was consistently less diverse than microbiomes from healthy 
subjects, with fewer total phyla, families, and species represented in the sequence collections, 
alongside much lower scores in a variety of diversity measures (Table 1). Intriguingly, the SCD 
treatment appeared to decrease the number of taxa represented in the post-diet 
sample. However, the post-diet bacterial community was more evenly distributed across 
multiple species as shown by Simpson’s and Shannon’s diversity indexes, as well as Pielou’s 
index of evenness (Table 1). Thus, overall diversity most likely increased post-diet and the 
decrease in total taxa is due to the low number of 16S sequences (less than half) from the post-
diet sample as compared to other samples. 
Analysis Control 1 Control 2 Control 3 Pre-Diet 1 Pre-Diet 2 Post-Diet 
16S Sequences 121,096 95,039 75,724 129,299 114,233 48,771 
Phylum 11 6 9 8 8 4 
Family 41 31 35 26 31 12 
Species 132 123 119 65 68 55 
d (Richness) 11.2 10.6 10.5 5.4 5.8 5.0 
J' (Evenness) 0.68 0.69 0.72 0.25 0.45 0.72 
Simpson's 0.94 0.95 0.95 0.37 0.70 0.91 
Shannon's 3.31 3.33 3.44 1.05 1.88 2.87 
TABLE 1: Diversity data from microbiome sequence analysis of control and patient 
samples. 
Included information: total number of QC-passed 16S rRNA gene sequences, representation of bacterial taxa at the phylum, 
family and species level, and four measures of species diversity for each sample. 
Prior to SCD treatment, Fusobacterium ulcerans, family Fusobacteriaceae, dominated the 
patient’s microbiome, comprising 83.22% to 53.61% of the sequences returned per sample at 
the family level, and 51.67% to 79.11% at the species level. The next most common species in 
the pre-diet samples was Viellonella dispar, family Veillonellaceae, comprising 18.91% to 2.6% 
at the family level, and 14.30% to 1.37% at the species level. No species from either of these 
families were detected in any of the healthy subject’s samples, with the exception of 
Veillonellaceae in Control 1. In contrast, the control microbiomes were dominated by species 
from the Bacteroideaceae, Ruminococcaceae, and Lachnospiraceae families. The patient’s post-
diet microbiome composition changed dramatically, with a decrease of Fusobacterium ulcerans 
to 23.11% and a marked increase in abundance of several species in the Enterobacteriaceae 
family (Tables 2-3). 
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Family Control 1 Control 2 Control 3 Pre-Diet 1 Pre-Diet 2 Post-Diet 
Bacteroidaceae 23.98 40.34 17.02 0.00 0.00 0.06 
Enterobacteriaceae 0.01 0.00 0.00 9.89 18.11 70.44 
Erysipelotrichaceae 1.15 0.23 1.66 0.39 2.11 0.75 
Fusobacteriaceae 0.00 0.00 0.00 83.22 53.61 25.47 
Veillonellaceae 0.15 0.00 0.00 2.60 18.91 1.32 
TABLE 2: Relative abundance of 16S rRNA gene sequences (percent of total). 
Comparison of key family-level groupings between control and patient samples to highlight family-level differences in microbiome 
composition. Not all families detected were included in this table. 
Genus species Control 1 Control 2 Control 3 Pre-Diet 1 Pre-Diet 2 Post-Diet 
Bacteroides spp. 1.30 3.49 0.81 0.00 0.00 0.06 
Enterobacter hormaechei 0.00 0.00 0.00 2.89 5.11 10.17 
Klebsiella oxytoca 0.00 0.00 0.00 0.00 0.00 3.69 
Klebsiella pneumoniae 0.00 0.00 0.00 0.22 0.43 0.09 
Salmonella enterica 0.00 0.00 0.00 0.18 0.34 0.64 
Escherichia coli 0.00 0.00 0.00 0.42 1.47 5.38 
Shigella flexneri 0.00 0.00 0.00 0.02 0.07 5.86 
Coprobacillus cateniformis 0.00 0.00 0.00 0.00 0.03 0.75 
Fusobacterium ulcerans 0.00 0.00 0.00 79.15 51.67 23.11 
Veillonella dispar 0.14 0.00 0.00 1.37 14.30 1.05 
TABLE 3: Relative abundance of 16S rRNA gene sequences (percent of total). 
Comparison of key species among control and patient samples to highlight species-level differences in microbiome composition. 
Not all species detected were included in this table. 
Discussion 
While this patient’s IBD was complicated by PSC and vancomycin treatment, Lee et al. showed 
that Fusobacterium spp. can be isolated from IBD patients and specifically from colonic ulcers 
[5]. The data collected in this case study supports previous evidence that Fusobacterium 
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may play a stimulatory role in IBD [6]. The therapeutic potential of the SCD is recorded in two 
observational studies assessing the effectiveness of the SCD [7], as well as an interventional 
study [4] analyzing patients’ microbiomes and serum biomarkers. Suskind et al. [4] observed 
immense variation in microbiomes across 12 pediatric IBD patients, as well as between 
patients’ pre- and post-dietary interventions. None of the patients in that study showed the 
changes in Fusobacterium spp. shown here. It is important to note that the diet was effective in 
decreasing symptoms in multiple patients, despite this variation [4]. Along with the Suskind et 
al. study, this case study supports the hypothesis that the SCD’s therapeutic actions stem from a 
change in microbiome composition. This case study identifies Fusobacterium ulcerans, a 
species not already noted in the literature as associated with IBD, as another potential target 
for dietary intervention. This study also documents the therapeutic success and intestinal 
microbial changes in an adult IBD patient as opposed to the pediatric patients in the Suskind et 
al. study. 
Although Fusobacterium dramatically decreased in relative abundance following the SCD, they 
remained the dominant species in this patient’s microbiome. Thus, the subject's improved 
symptoms could be due in part to an increase in other microbial species, rather than a decrease 
in Fusobacterium. In addition, Veillonella remained among the dominant species in the post-
diet sample, which is concerning since Kasai et al. report an increased risk of adenocarcinoma 
in the presence of both species [8]. In fact, Veillonella abundance was not clearly affected by the 
SCD, given the large pre-diet variation in Veillonella. This may be an important species to study 
in the future, considering its presence in many PSC patient microbiomes and rarity in healthy 
microbiomes. Despite a substantial post-diet increase in some species abundance, overall 
diversity did not rise to the level seen for control samples. While the short duration of the study 
and the patient’s antibiotic regimen may have limited visible effects, the SCD may not be able to 
fully correct IBD-related dysbiosis. 
Importantly, the SCD is not an effective symptom management regimen for every IBD patient. 
Some patients do not experience symptom relief no matter the duration of treatment. This lack 
of response may be explained by their microbiome; if the species identified by Suskind et al. 
and this study are not present in a patient’s microbiome, they may not experience a therapeutic 
microbiome shift. However, as shown in this case and in five out of 12 patients in Suskind et 
al., dietary intervention can have substantial effects on clinical symptoms, serum inflammatory 
biomarkers, and microbiome composition after just two weeks. 
The current leading drug treatments for IBD, including biologics and steroids, work downstream 
to decrease inflammation and thus treat symptoms. While Fusobacterium is not always present 
in IBD patients, it is present and increased in a large enough population that further 
investigation into the effects of the SCD on Fusobacterium is warranted and may contribute to 
upstream therapeutic agent development [9-10]. 
Conclusions 
The SCD was an effective therapy for IBD in this patient with IBD and PSC. Determining factors 
for SCD efficacy may involve the dominant intestinal bacterial species and may thus be patient 
specific, arguing for microbiome analysis as a diagnostic tool. While there are effective and 
potent downstream medications, it would be more advantageous to treat upstream causes of 
IBD. More research is needed to illuminate interactions between vancomycin dosing, PSC, 
microbial composition, and IBD symptoms and how they may differ between individual 
patients. 
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